Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

類似資料

• Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
  著者:: Strand, Vibeke, 等
  出版事項: (2019)
• Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
  著者:: de Vlam, Kurt, 等
  出版事項: (2021)
• Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
  著者:: Nash, Peter, 等
  出版事項: (2020)
• Measurement properties of the minimal disease activity criteria for psoriatic arthritis
  著者:: Coates, Laura C, 等
  出版事項: (2019)
• Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
  著者:: Kalyoncu, Umut, 等
  出版事項: (2016)